Adherence, Medication, AIDS, Antiretroviral Therapy, Highly Active, Drug-level Monitoring, HIV Infections
Conditions
Keywords
Adherence, Adult, Pharmacokinetics, Tenofovir, Viral Load
Brief summary
This observational study aims to investigate medication adherence and drug-level monitoring of antiretroviral agents in a cohort of people living with HIV in Indonesia. The study is conducted in outpatients receiving tenofovir-based regimens in a university medical centre.
Detailed description
Optimal adherence is critical to achieve and sustain viral suppression. Currently, there is no gold standard measure of antiretroviral adherence and exposure in clinical practice. Recent studies have evaluated the use of emerging biological matrices such as dried blood spots, urine, and saliva as means of objective adherence measures. For drug-level monitoring, tenofovir is selected as a drug of interest and thus only people receiving tenofovir disoproxil fumarate-based regimens will be monitored. Some studies have reported that higher plasma trough concentrations of tenofovir were associated with renal toxicity. Therefore, this project aims to measure level of adherence and tenofovir concentrations in plasma and emerging matrices among people living with HIV in Indonesia. Primary outcome is adherence to ART that will be measured using multi methods, including self-report questionnaire, pill counting, electronic monitoring, and drug-level testing. Secondary outcomes include tenofovir concentrations in plasma, urine, saliva, and dried blood spots and clinical outcomes (viral load and CD4 count). Assays for measuring tenofovir concentrations will be developed using high-performance liquid chromatography-tandem mass spectrometry. Concentrations derived from dried blood spots, saliva, and urine will be compared to plasma concentrations. Pharmacokinetic models will be used to interpret drug-level monitoring. The association of adherence measures as well as drug concentrations and clinical outcomes will be examined.
Interventions
None listed
Sponsors
Universitas Airlangga
Zamrotul Izzah
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults with HIV who have been receiving antiretroviral therapy containing tenofovir-based regimens for at least six months
Exclusion criteria
* Pregnant and breastfeeding women, people with kidney failure, undergoing hemodialysis or peritoneal dialysis, uncontrolled diabetes, uncontrolled hypertension, and hypersensitivity to tenofovir
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence to antiretroviral therapy | Baseline and 6 months | Adherence to antiretroviral therapy (ART) will be assessed using a validated Bahasa Indonesia version of self-reported adherence questionnaire. The questionnaire will recall ART use in the past week, past month, and past three months. The percentages of adherence will be calculated by the formula: (total number of dosage units prescribed - total number of times reported) / (total number of dosage units prescribed) × 100. The adherence scales range from 0 to 100% with higher scales denote higher adherence. Being highly adherent to ART is defined by having an adherence higher than 80%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tenofovir concentrations | Baseline (pre-dose, 1, and 4 h post-dose) and 6 months (random 3 - 16 h post-dose) | Concentrations of tenofovir in plasma, saliva, urine, and dried blood spots |
| Viral load | Baseline and 6 months | The viral load test will measure the number of HIV copies in plasma (in copies/ml). |
| CD4 cell count | Baseline and 6 months | The cluster of differentiation 4 (CD4) cell count test will quantify CD4 cells in plasma (in cells/mm\^3). |
Countries
Indonesia
Contacts
Primary ContactZamrotul Izzah
Backup ContactTri Pudy Asmarawati
Outcome results
None listed